Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$47.98 - $54.4 $2,830 - $3,209
59 Added 1.47%
4,077 $221,000
Q4 2023

Jan 10, 2024

SELL
$48.48 - $57.85 $14,495 - $17,297
-299 Reduced 6.93%
4,018 $206,000
Q3 2023

Nov 03, 2023

SELL
$57.89 - $64.73 $3,010 - $3,365
-52 Reduced 1.19%
4,317 $250,000
Q2 2023

Aug 02, 2023

SELL
$63.71 - $70.74 $2,420 - $2,688
-38 Reduced 0.86%
4,369 $279,000
Q1 2023

Apr 17, 2023

SELL
$65.71 - $74.53 $18,858 - $21,390
-287 Reduced 6.11%
4,407 $305,000
Q4 2022

Aug 03, 2023

BUY
$68.48 - $81.09 $22,256 - $26,354
325 Added 7.44%
4,694 $337,000
Q4 2022

Jan 18, 2023

BUY
$68.48 - $81.09 $68 - $81
1 Added 0.02%
4,694 $338,000
Q3 2022

Nov 04, 2022

BUY
$0.13 - $76.84 $16 - $9,758
127 Added 2.78%
4,693 $334,000
Q2 2022

Jul 21, 2022

BUY
$72.62 - $79.98 $508 - $559
7 Added 0.15%
4,566 $354,000
Q1 2022

Apr 13, 2022

BUY
$61.48 - $73.72 $23,792 - $28,529
387 Added 9.28%
4,559 $335,000
Q4 2021

Jan 12, 2022

SELL
$53.63 - $62.52 $21,344 - $24,882
-398 Reduced 8.71%
4,172 $260,000
Q3 2021

Oct 14, 2021

BUY
$59.17 - $69.31 $24,023 - $28,139
406 Added 9.75%
4,570 $273,000
Q2 2021

Jul 14, 2021

SELL
$61.91 - $67.42 $84,754 - $92,297
-1,369 Reduced 24.74%
4,164 $276,000
Q1 2021

Apr 23, 2021

BUY
$59.34 - $66.74 $65,095 - $73,213
1,097 Added 24.73%
5,533 $349,000
Q4 2020

Jan 25, 2021

BUY
$57.74 - $65.43 $5,138 - $5,823
89 Added 2.05%
4,436 $275,000
Q3 2020

Oct 20, 2020

SELL
$57.43 - $63.64 $9,016 - $9,991
-157 Reduced 3.49%
4,347 $268,000
Q2 2020

Jul 17, 2020

SELL
$54.82 - $64.09 $1,973 - $2,307
-36 Reduced 0.79%
4,504 $268,000
Q1 2020

Apr 17, 2020

SELL
$46.4 - $67.43 $5,336 - $7,754
-115 Reduced 2.47%
4,540 $253,000
Q4 2019

Jan 06, 2020

BUY
$49.21 - $64.19 $229,072 - $298,804
4,655 New
4,655 $297,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Winthrop Advisory Group LLC Portfolio

Follow Winthrop Advisory Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winthrop Advisory Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Winthrop Advisory Group LLC with notifications on news.